← Back to Search

Radiation-Free Whole Body MR Imaging for Childhood Cancer

Phase 1 & 2

Recruiting

Led By Heike Daldrup-Link

Research Sponsored by Heike E Daldrup-Link

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of a solid extra-cranial tumor like malignant lymphoma or malignant sarcoma

Very young children who need sedation or anesthesia will be excluded from the study

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial is testing if a new whole-body imaging technique can detect the extent and spread of disease in children as accurately as standard tests, but with less radiation exposure.

Who is the study for?

This trial is for children with solid tumors outside the brain, like lymphoma or sarcoma. They must be scheduled for or have completed a PET scan and can't be too young to require sedation. Consent from parents/guardians and assent from minors are needed.Check my eligibility

What is being tested?

The study tests new whole body MR imaging techniques using ferumoxytol contrast against standard CT and PET/CT scans to see if they're as good or better at finding how far cancer has spread, but with less radiation exposure.See study design

What are the potential side effects?

Potential side effects may include allergic reactions to the ferumoxytol contrast agent used in MR imaging, discomfort during the scan process, and anxiety related to undergoing multiple diagnostic tests.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with a type of cancer that is not in the brain.

Select...

My child does not require sedation or anesthesia for medical procedures.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Comparison of sensitivity, specificity and accuracy of WB-DW-MR scans to 18-F FDG PET scans.

Secondary outcome measures

Comparison of sensitivity, specificity and accuracy of Ferumoxytol-enhanced whole-body 18-F FDG PET/MR-scans versus standard clinical Gadolinium-enhanced whole-body 18-F FDG PET/MR-scans.